Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of JS212 and JS213 as monotherapy and in combination in advanced malignant solid tumors
CTR20260962Phase 2Active
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of JS212, JS213, JS207, toripalimab in renal cell carcinoma (RCC), prostate cancer (PCa), transitional cell carcinoma (TCC), melanoma, Non-hematologic malignancy, sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Apr 2026; status: active.
02
Drugs
JS212JS213JS207toripalimab
03
Conditions
renal cell carcinoma (RCC)prostate cancer (PCa)transitional cell carcinoma (TCC)melanomaNon-hematologic malignancy
Beyond the preview
Go deeper on CTR20260962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260962.